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Abstract
Systemic lupus erythematosus (SLE) mainly affects women in the fertile age 
of life. A patient with SLE is as fertile as the general population except for treat-
ment with drugs with ovarian toxicity, severe flare of the disease, or autoimmune 
oophoritis for anti-ovarian antibodies. Pregnancy in a woman with SLE implies 
greater maternal and fetal mortality and morbidity. Fetal loss, premature birth, 
intrauterine growth restriction associated with antiphospholipid antibodies 
(aPL), and neonatal lupus associated with anti-Ro are important fetal problems. 
Similarly, preeclampsia and lupus nephritis may lead to diagnostic confusion. 
Treatment options during pregnancy are limited to a few safe medications, 
which further restricts options. The loss of refractory pregnancy associated with 
antiphospholipid antibodies and the complete heart block associated with anti-Ro 
antibodies remain unresolved problems. The planning of pregnancy with sustain-
able treatments during pregnancy, no flare of SLE in the previous 6 months, and 
absence of nephritis are important for a good maternal and fetal prognosis. A 
gestation planning, multidisciplinary approach, and close monitoring are essen-
tial to obtain optimal results.
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1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease that predomi-
nantly affects women of fertile age. Pregnancy causes concern for the majority of 
patients with SLE. The risk of the disease flare during pregnancy, the possibility of 
fetal loss, and the safety of drugs during pregnancy are of concern. A better under-
standing of the pathogenesis of SLE and good use of immunosuppressive drugs 
allows us to better control the disease, and we should not deprive patients with SLE 
of the opportunity to have children. Prepregnancy information and collaboration 
between specialists, such as obstetricians and perinatologists, are essential to opti-
mize maternal and fetal outcomes in SLE pregnancies. In this chapter, important 
issues related to fertility, optimal time of conception, risk of disease flare during 
pregnancy, course of pregnancy, fetal outcome, safety of various medications used 
to control SLE during pregnancy and lactation, and a contraceptive education are 
discussed [1].
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2. Systemic lupus erythematosus fertility
Fertility in patients with SLE is not greatly affected by the diagnosis of the 
disease. The decrease in fertility in SLE can be a consequence of the drugs used in 
the treatment of these patients, the flare of the disease, the organic damage caused 
by the disease, or advanced age. The use of cyclophosphamide (CYC) induces the 
majority of nonage-related infertility in patients with SLE, although the increasing 
use of mycophenolate mofetil (MMF) for the treatment of renal and extrarenal 
manifestations reduces the incidence due to its null ovarian toxicity. The risk of 
infertility due to CYC is associated with both the cumulative dose and an older age 
(>37 years old) of the woman at the time of treatment. The probability of maintain-
ing fertility after treatment is greater for patients under 30 years of age, six or less 
monthly intravenous pulses, a cumulative dose of less than 7 g, and lack of amenor-
rhea before or during drug administration. It is less likely that other treatments in 
SLE have a significant impact on fertility, although nonsteroidal anti-inflammatory 
drugs (NSAIDs) have been suggested as possible contributors to infertility and it is 
suggested that high doses of corticosteroids have some effect on the cycle menstrual 
through its effect on the hypothalamic pituitary axis (HPA).
Patients with SLE may have menstrual disturbances or even amenorrhea second-
ary to very active disease. In addition, serum levels of anti-mulleriana hormone 
(AMH) are lower in patients with SLE not treated with CYC than in controls 
matched by age. It is important to emphasize that renal failure induced by lupus 
glomerulonephritis can cause hypofertility or infertility due to an alteration of the 
HPA, which can be reversed with kidney transplantation.
The profile of autoantibodies does not seem to affect fertility in women with 
SLE. However, the study of aPL in women with lupus is essential for predicting 
gestational risk, although recent controlled studies do not support an association 
between aPL and infertility or in vitro deficient fertilization (IVF). Evaluation or 
treatment of aPL in infertile women is not recommended.
Older age is an important factor of infertility in SLE, as it is in the general 
population. Female fertility decreases with age due to the progressive loss of the 
ovarian reserve; many patients with SLE are older when they try to conceive and 
may encounter difficulties related to age. The onset of SLE is more frequent in the 
first years of reproduction, and it is advised to avoid pregnancy when the disease 
is active. Premature ovarian failure (persistent amenorrhea with elevated levels 
of follicle-stimulating hormone before age 40) may be of autoimmune etiology in 
the general population but is rarely associated with systemic autoimmune diseases 
such as SLE [1, 2]. The study of anti-ovarian antibodies has contributed little to this 
pathology. However, treatment with corticosteroids and/or immunosuppressants 
has reversed the process in some cases.
2.1 SLE fertility preservation
Preserving fertility in women with SLE involves limiting cytotoxic drugs when 
possible and protecting the ovaries during treatment; however, prompt and effec-
tive therapy for a severe disease often takes precedence. The cryopreservation of 
oocytes or embryos is an effective option but requires ovarian stimulation, which 
may be impractical given the usual need to institute therapy quickly to avoid dam-
age, as well as the risk of hyperstimulation in a patient with active SLE. The age of 
the patient to whom CYC is administered is not modifiable, but an effort must be 
made to minimize the total dose of CYC. The use of MMF may be the best option. 
Treatment with agonists of the gonadotrophic hormone receptor (GnRH) during 
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CYC therapy to minimize ovarian toxicity has become a common practice. Ovarian 
toxicity amenorrhea due to CYC has been the classic clinical sign. Now, the mea-
surement of the AMH provides us with a better evaluation of the ovarian reserve. In 
a study of patients with SLE who received leuprolide with a GnRH agonist between 
10 and 14 days before the CYC pulse therapy, a 68% increase in the ovarian reserve 
was estimated compared to patients with SLE who had not received this treatment. 
The GnRH agonist should not be administered immediately before the CYC. When 
administered during the follicular phase of the cycle, it can stimulate the ovaries 
and worsen ovarian damage. Patients without therapy with GnRH agonists before 
their first infusion can start treatment after the first cycle and receive treatment at 
monthly intervals thereafter [2].
3. Contraception control
SLE patients may be strongly advised to avoid pregnancy, particularly when 
they have severe disease-related damage or active disease or are taking terato-
genic medications. Consequently, contraceptive options should be discussed with 
all female patients of reproductive age. Counseling patients to defer pregnancy 
relies on the assumption that they will utilize safe and effective contraception. In 
practice, SLE patients currently underutilize effective contraception, even those 
taking teratogenic medications [2]. Contraceptives vary in safety and efficacy. 
Long-acting reversible contraceptives such as intrauterine devices (IUDs) or 
subdermal implants have the greatest efficacy. IUDs generally contain either 
progesterone (levonorgesterol) or copper. Although IUDs have a low risk of 
infection, patients treated with immunosuppressive medications have not been 
specifically studied. However, HIV-infected women who have been studied do 
not have a greater risk of infection. Combined hormonal contraceptives include 
the pill, transdermal patch, and vaginal ring. Serious side effects include a 
three- to fivefold increased risk of venous thromboembolism and a twofold 
increased stroke risk. Medications commonly used for patients with SLE, such 
as warfarin and MMF, may interact with these agents and alter their efficacy. 
Concern regarding estrogen-induced flare previously has limited the use of oral 
contraceptives in patients with SLE. Two recent prospective studies in women 
with stable SLE showed no increased risk of flare with combined oral contracep-
tives. But oral contraceptives containing the progestin drospirenone can increase 
serum potassium and be dangerous in patients with nephritis or who also take 
angiotensin-converting enzyme (ACE) inhibitors. The vaginal ring and the patch 
may further increase thrombosis risk compared to oral combined contraceptives, 
and their safety in SLE has not been studied. No forms of estrogen-containing 
contraceptives are advised for use in aPL-positive patients due to the increased 
risk for thrombosis [3]. Progesterone-only contraceptives include oral and intra-
muscular forms, IUDs, and a subdermal etonogestrel implant. Depot medroxy-
progesterone acetate (DMPA) injections may decrease bone density when used 
chronically, a concern in corticosteroid-treated patients. Progesterone-only 
contraceptives represent a safe and effective option for aPL-positive patients; 
with the possible exception of DMPA, the risk for thromboembolism is very low, 
and they may decrease menstrual blood loss. Emergency contraception can be 
considered for all SLE patients, including aPL-positive patients. Long-acting 
reversible contraceptives are preferable for most SLE patients, but every decision 
regarding contraception must balance the risk and efficacy of the method with 
the risk of unplanned pregnancy.
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4. Fertility and assisted reproductive techniques
Fertility is generally unimpaired in patients with systemic lupus erythematosus 
(SLE), unless they have been treated with cyclophosphamide (CYC). Although 
CYC is less commonly used for nephritis than in the past because of the availability 
of MMF, prevention of CYC-induced infertility remains an important concern. 
Concurrent gonadotropin-releasing hormone (GnRH) analogue therapy, usually 
leuprolide, appears to decrease risk of premature ovarian failure by CYC. Embryo 
and oocyte cryopreservation is options to preserve fertility in patients who are 
stable enough to safely undergo ovarian hyperstimulation. Patients with lupus may 
undergo assisted reproduction techniques, including in vitro fertilization (IVF). 
Ovarian hyperstimulation syndrome (OHSS) is a rare complication of IVF resulting 
in a capillary leak syndrome; severe OHSS increases risk for thrombosis and renal 
compromise. Even in a well-controlled cycle, elevated estrogen levels may increase 
risk of flare and thrombosis in SLE patients. However, thrombosis in aPL-positive 
patients undergoing IVF is rare, but most reported patients have been treated pro-
phylactically with anticoagulants. Prophylactic anticoagulation may be considered 
in patients with high-risk aPL profiles and is mandatory for those with confirmed 
APS. However, aPL antibodies as a cause of failed IVF or infertility is not accepted, 
and anticoagulation is not indicated to improve IVF cycle outcome [2, 3].
5. Preconception orientation
Good information to the patients and pregnancy planning is essential for a 
woman with SLE who wants a child. Pregnancy planning is a key point for women 
Preconception visit checklist Contraindications to pregnancy
Age Severe lupus flares within the 
previous 6 months
Any previous pregnancy? Severe restrictive lung disease 
(FVC < 1 L)
Previous pregnancy complications? Heart failure
Presence of severe irreversible damage? Chronic renal failure (Cr < 30 mg/dL)
Recent or current lupus activity? Stroke within the previous 6 months
Presence of antiphospholipid antibodies/syndrome? Previous severe preeclampsia of 
HELLP syndrome despite therapy 
with aspirin and heparin
Other chronic medical conditions? Severe lung hypertension
(Hypertension, diabetes, etc.) (Estimated systolic PAP > 50 mm Hg 
or symptomatic)
Previous nephritis or active nephritis
Current treatment: any forbidden drugs
(including cyclophosphamide, methotrexate, mycophenolate, 
thalidomide, or thalidomide lyks, angiotensin-converting, enzyme 
inhibitors, angiotensin II receptor blockers, diuretics, and statins)
Positive anti-Ro and anti-La
Anti-DNA, complement levels C3 and C4
Abbreviations: PAP, pulmonary arterial pressure; FVC, forced vital capacity.
Table 1. 
Preconception visit checklist and contraindications to pregnancy in women with SLE.
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with SLE. Postponing conception until the disease is inactive for at least the previ-
ous 6 months significantly improves the results. Women with irreversible lesions in 
vital organs are more likely to suffer maternal-fetal morbidity and mortality during 
and after pregnancy. The pregnancy should be delayed, such as a severe disease 
flare in the previous 6 months, a recent stroke, and active lupus nephritis. In some 
situations, pregnancy may be contraindicated (Table 1). A profile of autoantibod-
ies, such as aPL (anticardiolipin, anti-β2 glycoprotein I, and lupus anticoagulant), 
serum levels of complement, anti-SSA, and anti-SSB antibodies [4], is essential as 
risk factors for complications during pregnancy. Keeping the SLE inactive and the 
function of organs with safe medications during pregnancy should be a goal. There 
is an increased risk of complications among women with severe impairment of 
organ function, with or without serious pre-existing damage. The care of pregnant 
women with SLE must focus on three mainstays: a coordinated medical-obstetrical 
care, a well-defined management protocol, and a well-structured prenatal 
follow-up.
6. Laboratory evaluation during prenatal care
In pregnancy, it is necessary to perform routine pregnancy testing plus other 
tests that include a complete blood count, kidney and liver function, and proteins in 
a 24-hour urine collection (Table 2). Complementary studies should include addi-
tional tests such as complement study (C3 and C4), aCL, LA, aβ2GPI, anti-DNA, 
anti-SSA, and anti-SSB antibodies [4]. Evaluate the activity of the disease during 
the prenatal phase. The hormonal changes during pregnancy cause an alteration 
of the domain of Th1 to Th2 lymphocytes, and, consequently, it is expected that 
autoimmune disorders involving the Th2 response, such as SLE, are activated. In 
general, it is accepted that pregnancy can lead to higher rates of outbreaks of the 
disease, ranging from 25 to 65%. Skin rashes and musculoskeletal symptoms are less 
common, while renal and hematological flares are more frequent. The risk of flare 
seems to be related to the onset of disease activity 6–12 months before conception. 
There is an increased risk of flares during pregnancy when there is lupus nephritis 
at conception and even in women with pre-existing nephritis in remission. One 
study showed an exacerbation rate of 30% of SLE activity during pregnancy or 
postpartum in women with pre-existing lupus nephritis. It is sometimes difficult to 
distinguish signs and symptoms related to pregnancy from those due to SLE. Some 
ambiguous manifestations such as fatigue, headaches, arthralgias, edema, hair loss, 
palmar and malar erythema, anemia, and thrombocytopenia can be confused with 
clinical manifestations of SLE. An evaluation by physicians experienced in pregnant 
women with SLE is important. Blood tests with basal blood counts and urinalysis 
with measurement of proteinuria are useful to control the state of the disease and 
identify the flare. The production of C3 and C4 increases in the liver during preg-
nancy, and, therefore, their levels may be within the range of normality in cases of 
active SLE. Relative variations of complement are more important than absolute 
levels, and a 25% drop in serum complement levels may suggest a flare of lupus. The 
determination of the products of complement degradation would be the best way 
to identify a greater activation. Currently, we have indices to measure the activity 
of SLE during pregnancy, such as the pregnancy activity index of systemic lupus 
erythematosus (SLEPDAI) and the index of lupus activity in pregnancy (LAI-P). 
In practice, the clinical judgment of an experienced clinician is still considered 
the gold standard, and these indices are essential for publications on SLE and 
pregnancy. The SLEPDAI scale is an instrument similar to the SLE disease activity 
index (SLEDAI) to evaluate the activity of lupus, assigning different scores for the 
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various clinical and laboratory manifestations of lupus activity, however, taking 
into account the changes, physiological factors of pregnancy, and main pathologies 
of the pregnancy-puerperal cycle that can simulate an active SLE. The risk of hyper-
tensive disorders during pregnancy increases in the context of active lupus nephri-
tis. The frequency of preeclampsia varies from 7.5 to 22.5% for all women with 
SLE. Renal involvement of lupus is often associated with hypertension, and the 
diagnosis of preeclampsia is difficult because it may coincide with chronic hyper-
tension exacerbated during pregnancy. Likewise, in the case of women with SLE 
with residual glomerular lesions, an increase in proteinuria can be observed, due to 
the increase in the glomerular filtration rate during pregnancy, and this fact is not 
related to preeclampsia. The diagnosis of preeclampsia may be more difficult due to 
the increase in blood pressure and previous proteinuria. The differential diagnosis 
of preeclampsia in patients with lupus may be facilitated by changes in the C3, C4, 
and CH50 measurements, since a reduction in these levels is expected during lupus 
activity. Other laboratory tests are useful to perform a differential diagnosis, such as 
an abnormal urinary sediment, erythrocytic dysmorphia or cell casts, and increased 
titers of anti-DNA antibodies (common in lupus nephritis). SLE of onset during 
pregnancy should be considered as an active lupus and may be associated with a 
worse outcome of pregnancy. Differentiating preeclampsia into an early SLE during 
pregnancy is a challenge and often delays the diagnosis of SLE. Among patients 
with stable SLE at the time of conception, it is expected that the activity of the 
disease does not worsen, and even if so, the flare is usually mild and involves some 
type of treatment modification.
7. Evaluation of fetal growth and vitality
Fetal complications are frequent in patients with SLE. Miscarriages and intra-
uterine fetal death can occur in 20% of pregnancies in patients with SLE. Patients 
Prepregnancy Every 6–8 weeks1
Complete blood count with platelets Complete blood count with platelets
Comprehensive metabolic panel Comprehensive metabolic panel
Prothrombin time/partial thromboplastin tine Urinalysis with microscopy
Urinalysis with microscopy Spot protein/creatinine ratio
24-hour urine protein and creatinine clearance2 Anti-dsDNA
Spot protein/creatinine ratio Complement levels (C3, C4)
Anti-dsDNA Uric acid
Anti-Ro/SSA and anti-La/SSB antibodies sFlt-1/PlGF ratio (>20 weeks)
Lupus anticoagulant3
Anticardiolipin IgG, IgM3
Anti-β2 glycoprotein I IgG, IgM3
Complement levels (C3, C4)
Uric acid
1Adjust interval of monitoring based on clinical situation.
2In patients with proteinuria, consider repeating 24-hour urine test each trimester.
3If positive for first time, repeat in 12 weeks.
Table 2. 
Systemic lupus erythematosus pregnancy evaluation and monitoring.
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with a history of nephritis have a higher risk of such adverse outcomes. The rate 
of restriction of fetal growth (FGR) is close to 30%, even in mild disease, with 
an increased risk if there is renal involvement. Several studies concluded that the 
result of the mortality rate for women with SLE tends to be higher, a condition 
strongly associated with the presence of flares of the disease during pregnancy. 
Serial obstetric ultrasound is the most important method to guide the monitor-
ing of fetal growth. The measurement of the length of the cranial crown in the 
first trimester is presented as the most accurate measurement. At 16–22 weeks of 
gestation, an anatomical survey should be followed that considers the diagnosis 
of fetal anomalies, which also allows the first growth monitoring. In each 4-week 
period, new scans must be performed, measuring the volume of amniotic fluid. If 
preeclampsia is diagnosed, the interval should be reduced. The monitoring of fetal 
vitality is an important part of the prenatal care of patients with SLE. This should 
include the nonstress test (NST), the biophysical profile (BPP), and the Doppler 
velocimetry of the fetal umbilical artery, beginning at 26–28 weeks and continuing 
weekly until birth. In patients with SLE, alterations of the umbilical artery Doppler 
velocimetry should be handled in a similar way to those without the condition. The 
normal evaluation of these tests has a high negative predictive value for fetal death. 
A relationship exists between abnormal uterine artery Doppler and posterior fetal 
loss, preeclampsia, FGR, and preterm birth. For women with anti-SSA/anti-SSB 
antibodies, fetal echocardiography should be performed between 18 and 26 weeks 
to exclude congenital heart blockage of the fetus. An urgent referral to a tertiary 
care center should be requested in case of abnormal fetal heart rate, mainly a low 
heart rate.
8. Recommended SLE treatment during pregnancy
An active SLE is harmful to the mother and the fetus, and an appropriate 
reflection is necessary between the risks and benefits of the indicated treatment. 
In practice, it is common for women with SLE to interrupt their medication before 
conception, for fear of fetotoxicity, which happens through medical advice and 
proper planning [5]. Stopping the medication can lead to an active SLE and unfa-
vorable pregnancy outcomes. Immunosuppressive treatment in pregnant women 
with quiescent lupus should not be changed unless it induces fetal malformations. 
The glucocorticoids and antimalarials are the drugs most used in the treatment of 
lupus and should be maintained at the same doses during pregnancy. Prednisone 
at a dose of 5–10 mg/day is considered safe and sustainable during pregnancy. 
The mild flare of the disease can be treated with low doses of prednisone (less 
than 20 mg/day), and higher doses of corticosteroids, such as intravenous pulses, 
will be indicated to treat moderate to severe lupus activity. The antimalarial is not 
teratogenic and is recommended to prevent the activity of the disease and reduce 
the risk of cardiac neonatal lupus in patients with anti-Ro antibodies. The use of 
immunosuppressants is possible during pregnancy, and azathioprine is the saf-
est. Changing other immunosuppressants to azathioprine in a patient with SLE 
who wants pregnancy is recommended. Some recent report describes leukopenia, 
thrombocytopenia, and slow development of children exposed to azathioprine 
during pregnancy. Cyclosporine and tacrolimus, classified as category C by the 
Federal Drug Association (FDA), are safe during pregnancy initially demonstrated 
in pregnant women with kidney transplantation. CYC should not be prescribed 
during the first trimester for causing fetal chromosome, if it can be used during 
the second or third trimester for severe flares not controlled with pulses of methyl-
prednisolone or other immunosuppressants. The use of CYC during the second and 
Lupus
8
third trimesters does not seem to increase the risk of congenital anomalies, although 
spontaneous abortions and premature labor may be more frequent. Treatment with 
mycophenolate mofetil may be another option during the second and third trimes-
ters, although more experience is lacking. Leflunomide is associated with terato-
genic and fetotoxic effects in animals, and its metabolite is detectable in plasma up 
to 2 years after the interruption. In pregnant women, it is formally contraindicated, 
and pregnancy should be excluded before starting a treatment with leflunomide. 
Methotrexate, classified as drug X by the FDA, is teratogenic and produces abor-
tion at high doses; therefore, it is contraindicated in pregnancy. If used in the first 
trimester, it is associated with FGR and some important malformations, such as 
absence or hypoplasia of the frontal bones, craniosynostosis, large fontanelle, and 
ocular hypertelorism. Thalidomide or thalidomide-like is used for the treatment 
of cutaneous lupus, producing malformations in the fetus, such as phocomelia 
by thalidomide. Rituximab has a very low transplacental transfer during the first 
trimester of pregnancy, and some studies of safe pregnancies and deliveries have 
already been reported in cases of exposure; in the second or third trimester, it can 
cross the placenta and induce severe neonatal lymphopenia. Therefore, in these 
cases, live vaccines should be avoided in these children during the first 6 months 
of life. High blood pressure is a common condition among patients with lupus 
nephritis; an adequate treatment of blood pressure during pregnancy can reduce 
the progression of the disease and avoid several adverse pregnancy outcomes. The 
labetalol, nifedipine, hydralazine, and methyldopa are safe medications to treat 
hypertension in pregnant women. Angiotensin-converting enzyme (ACE) inhibi-
tors should be avoided due to their association with multiple congenital anomalies. 
A low dose of aspirin is recommended, since it reduces the risk of preeclampsia and 
perinatal death; In addition, it is associated with an increase in birth weight in those 
cases with risk factors, including kidney disease. Complete anticoagulation with 
low molecular weight heparin (LMWH) is recommended if there has been a previ-
ous thrombotic event. Calcium supplements are required, mainly for those women 
who use corticosteroids and heparin. Also, vitamin D supplements can be given, but 
it does not reduce unfavorable obstetric risks.
9. Lupus flare management during pregnancy
Many physiological changes in pregnancy can overlap with the characteristics 
of active disease, which makes differentiation difficult (Table 3). Some common 
laboratory tests also become less reliable: mild anemia and thrombocytopenia are 
common, the erythrocyte sedimentation rate (ESR) increases, and up to 300 mg/day 
proteinuria can occur during normal pregnancy. Complement levels increase by 
10–50% during normal pregnancy and may appear to remain in the “normal” 
range, despite the activity of the disease. Anti-DNA antibodies may be useful in 
the evaluation of disease activity. The scales of activity of the specific disease of 
pregnancy, the activity index of pregnancy SLE (SLEPDAI), the LAI-P, and the 
BILAG2004-Pregnancy index have been developed with modifications in the 
descriptors. A combination of laboratory parameters along with clinical judgment 
may be the best tool to evaluate the activity of the disease. Based on the numerous 
risks associated with pregnancy, it is recommended that women with SLE have a 
preconception assessment and multidisciplinary management with maternal-fetal 
drugs and rheumatology during pregnancy. Active SLE at the time of conception 
is a predictor of adverse outcomes. It is suggested that the disease remain inac-
tive for 6 months before attempting pregnancy. Laboratory tests should include, 
at a minimum, antiphospholipid antibodies (LA, IgG and IgM aCL, IgG, and 
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IgM anti-aβ2GPI I antibodies), anti-Ro/SSA and anti-La/SSB antibodies, and 
an evaluation of renal function (creatinine, protein/creatinine ratio in urine). 
Women who have anti-Ro/SSA and anti-La/SSB antibodies should have intensive 
fetal monitoring for cardiac arrest with fetal echocardiography by weekly pulsed 
Doppler (to measure the mechanical PR interval) beginning at 16–18 weeks and 
continuing up to 26–28 weeks of pregnancy. Ideally, all women with SLE should 
receive HCQ and low doses of aspirin during pregnancy, unless contraindicated. 
Women who continue HCQ during pregnancy have fewer outbreaks of disease 
and better outcomes as well as mothers with positive anti-Ro/SSA and anti-LA/
SSB antibodies. Low-dose aspirin initiated at 12–16 weeks of gestation reduces 
the risk of preeclampsia and fetal growth restriction [6]. The interruption of 
medications used to control the activity of the disease increases the risk of flares 
and complications associated with pregnancy. Serial ultrasound exams should 
be performed to assess fetal growth and fetal monitoring before delivery should 
begin in the third trimester. Renal involvement is common in patients with SLE 
and may be suspected in the presence of proteinuria or elevated serum creati-
nine. Hypertension and nephrotic syndrome consist of intense proteinuria, 
hypoalbuminemia, and peripheral edema, and patients have characteristically 
low levels of complement (C3) and high levels of anti-DNA. The involvement 
of the renal vasculature in cases of lupus nephritis is a sign of poor prognosis. In 
thrombotic microangiopathy, damage to the endothelial cells of small arterioles 
and capillaries results in thrombosis and mortality. Neuropsychiatric symptoms 
observed should be considered and excluded, including electrolyte abnormalities, 
infection, renal failure, and the effects of drugs. In the absence of a standard gold 
diagnostic test, this can represent a significant clinical challenge, especially in 
pregnancy and the postpartum period, where specific conditions of pregnancy, 
such as preeclampsia and eclampsia, can produce the same symptoms. The APS is 
an autoimmune disorder characterized by vascular thrombosis and/or pregnancy 
morbidity in the presence of persistent antiphospholipid antibodies. A small 
subset of patients with APS (<1%) develops multiple organ failure secondary to 
a disseminated thrombotic disease, a condition called catastrophic APS (CAPS) 
that has a mortality rate of up to 50%.
Pregnancy changes SLE activity
Clinical features Facial flush Photosensitive rash
Palmar erythema Oral or nasal ulcers
Arthralgias Inflammatory arthritis
Fatigue Fatigue, lethargy
Mild edema Moderate to severe edema
Mild resting dyspnea Pleuritis, pericarditis
Laboratory features Mild anemia Immune hemolytic anemia
Mild thrombocytopenia Thrombocytopenia
Leukopenia, lymphopenia
Mild increased ESR Increased inflammatory marker levels
Physiologic proteinuria Proteinuria > 300 mg/day
Active urinary sediment
Abbreviation: ESR, erythrocyte sedimentation rate.
Table 3. 
Overlapping features of pregnancy and systemic lupus erythematosus (SLE).
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The treatment of flares during pregnancy is guided by the severity and involve-
ment of the organ, similar to the state of nonpregnancy. However, the choice of 
agents is limited to safe medications, as discussed above. The steroids should be 
used in the lowest possible doses, but short cycles of high doses can be used for flare 
control. NSAIDs can produce malformations, and in general their indication in 
the SLE is in disuse. The antimalarial should be continued throughout pregnancy. 
Azathioprine and anti-calcineurin can occur throughout pregnancy. Azathioprine 
is a safe immunosuppressant with much experience in pregnancy, although delays 
in the development of the offspring have recently been reported. IVIg and plas-
mapheresis are still alternative options, but the increased risk of thrombosis with 
IVIg and fluid overload should be considered, although it is rarely necessary if 
we exclude intravenous Ig treatment of severe thrombocytopenia in pregnancy. 
Physiological changes in pregnancy such as an increase in glomerular filtration rate 
and renal plasma flow can worsen pre-existing kidney disease. However, in theory, 
a rapid decrease in the levels of the pregnancy hormone, particularly estrogen, 
may be advantageous. It is known that the immunosuppressive drugs used to treat 
SLE, such as CYC, cross the placenta and have teratogenic effects. In addition, this 
particular medication has been associated with premature and irreversible ovarian 
failure.
10. Lupus pregnancy, nephritis, and eclampsia
Lupus nephritis is an important risk factor for both maternal and fetal compli-
cations. A meta-analysis of 37 studies from 1980 to 2009 included 2751 pregnancies 
with SLE: the SLE flare rate was 25.6%, and the rates of preterm birth and IUGR 
were 39.4 and 12.7%, respectively. Positive associations were identified between 
preterm birth and active nephritis, hypertension and active nephritis, and pre-
eclampsia and history of nephritis [7]. Up to 25% of women with SLE will develop 
preeclampsia compared to 5% in the general population. Doctors who treat lupus 
and pregnancy should ask themselves questions like does the presence of increased 
proteinuria and hypertension represent a flare or does the presence of increased 
proteinuria and hypertension represent the onset of preeclampsia? At the begin-
ning of pregnancy, the presence of new or worsening proteinuria and hypertension 
will almost always represent a flare of lupus nephritis. However, beyond 20 weeks 
of gestation, differentiating a flare of preeclampsia poses a diagnostic as well as a 
therapeutic challenge (Table 4). Flare of lupus nephritis in pregnancy may be the 
first presentation of lupus and is relatively rare in those without previous nephritis 
or inactive nephritis at the beginning of pregnancy. However, if a woman has pro-
teinuria, hypertension, renal function decreased at the beginning of pregnancy, 
and a history of lupus nephritis, she is likely to have a flare of lupus nephritis. The 
clinical history plus appropriate biochemical investigations is key to the diagnosis 
of clinical complications in SLE and pregnancy. The complement should be normal 
or high in pregnancy because it behaves as an acute phase reactant since this is 
pregnancy. The decrease in complement, even within the normal range, should 
alert us to a possible flare of SLE and more when associated with an increase in 
anti-dsDNA. If proteinuria is significant and unexpected, it can mean a change in 
immunosuppression and even renal biopsy if the woman is in the first trimester or 
in part during the second trimester, although it is only necessary if the clinic and 
laboratory are discordant. Always keep in mind if the woman is at risk of bleeding 
after the biopsy and for how long anticoagulation can be delayed in a pregnant 
woman with intense proteinuria and possibly phospholipid antibodies who, 
therefore, have a high risk of thrombovenous embolism, since the procoagulant 
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factors are added, pregnancy, nephropathy, SLE activity, and/or aPL. If the risk 
of having thromboembolism outweighs the benefit of a firm diagnosis, a biopsy 
should not be done. However, if there is a biochemistry compatible with a flare of 
lupus, patient’s history contains nephritis flares and it is seems that it is going to 
be repeated; a kidney biopsy could be justified. The distinction of nephritis from 
lupus of pregnancy preeclampsia (from 26/40 weeks of gestation) can be difficult. 
In both, there will be an increase in proteinuria, hypertension, generalized symp-
toms, thrombocytopenia, and kidney damage. In women with isolated preeclamp-
sia, there should be no hematuria, urinary cylinders, a decreasing complement, 
or increasing anti-dsDNA. However, a flare of lupus nephritis increases the risk of 
preeclampsia, so, again, distinguishing the two can be a challenge for the clinician. 
The two treatments are different; preeclampsia requires delivery sooner rather 
than later, and lupus nephritis requires immunosuppressive treatment. It is not yet 
a usual practice, but it is likely to be exceptionally useful, measuring angiogenic 
and antiangiogenic factors, to determine if there is preeclampsia present. Women 
with APS and SLE who developed preeclampsia had a median of sFlt-1 (tyrosine 
kinase similar to soluble fms), low placental growth levels (PIGF), and a signifi-
cantly higher sFlt-1/PlGF ratio, and significantly higher PIGF levels lower com-
pared with women with APS and SLE and without preeclampsia after 12 weeks of 
gestation. These differences increased with gestational age. The sFlt-1/PlGF ratio 
became a significant predictor of preeclampsia at 12 weeks, showing the highest 
levels at 20, 24, and 28 weeks of gestation [8, 9]. Later, the fall of the placental 
growth factor predicted the appearance of preeclampsia even in women with 
pre-existing chronic kidney disease. A recent publication highlights the evidence 
(or more commonly the lack of evidence) for the best use of antirheumatic drugs 
before and during pregnancy. Women who take azathioprine, hydroxychloroquine, 
cyclosporine, and tacrolimus can safely breastfeed their babies, so women who 
take these medications should not be discouraged from breastfeeding.
Clinical measure Preeclampsia Lupus nephritis
Time >20 weeks >20 weeks
Hypertension Present Often present
Urine active sediment Rare Common
Onset of proteinuria Abrupt, after 20 weeks Abrupt or gradual, anytime
Uric acid >4.9 mg/dl <4.9 mg/dl
C3 and C4 Usually normal Usually low or decreasing
Complement products Normal Usually higher
Anti-DNA Negative or stable Positive or increasing
Lupus activity No Yes
Urine calcium <195 mg/day >195 mg/day
Thrombocytopenia Yes (HELLP) 20% of SLE
Liver function test May be elevated (HELLP) Usually normal
Kidney biopsy Glomeruloendotheliosis SLE nephritis
sFlt-1/PlGF ratio Higher Normal
Abbreviations: HELLP, hemolysis, elevated liver enzymes, and low platelets; SLE, systemic lupus erythematosus; sFlt-1, 
soluble fms-like tyrosine kinase; PlGF, placental growth factor.
Table 4. 
Differentiation of preeclampsia from lupus nephritis flare in pregnancy.
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There are still no safety data on the MMF, so breastfeeding is discouraged if 
MMF is required. The woman with SLE and pregnancy should be treated as high-
risk. At the controls ask for symptoms of the disease to detect SLE flare, and always 
check the blood pressure to detect preeclampsia. A blood and urine test should be 
done every quarter to detect biological changes in the complement and anti-DNA 
that suggest a flare. The fetus must be carefully monitored to detect growth and 
blood flow. Good multidisciplinary coordination among obstetrician, nephrolo-
gists, rheumatologists, and nursing experts is essential for better results.
11. Pregnancy and antiphospholipid antibodies
Pregnancy in women with SLE and aPL-positive courses with obstetric is 80% 
of cases. The current standard treatment for patients with obstetric includes LDA 
(75–100 mg/day) and low molecular weight heparin (subcutaneous enoxaparin, 
dalteparin, nadroparin, or subcutaneous tinzaparin) or unfractionated heparin. 
These recommendations are based on the results of randomized controlled trials 
comparing LDA alone or in combination with heparin with APS [7]. Kutteh et al. 
reported a significant improvement in the rate of live births with LDA and heparin 
versus LDA alone (80 versus 44%, P < 0.05). Rai et al. showed a significantly higher 
rate of live births with LDA and unfractionated heparin (5000 units) versus LDA 
alone (71 versus 42%, OR, 3.37, 95% CI, 1.40–8.10). However, no differences were 
found in the results with the combined treatment versus the LDA in two other ran-
domized trials, both with LMWH, with live birth rates close to 80% in both groups. 
The heterogeneity in the findings seems to be attributed to the relatively poor 
results in women who received LDA alone in the two previous studies. In addition, 
data from observational studies have reported pregnancy success rates of 79–100% 
with LDA alone in this subgroup of women, although many of these cases had low 
levels of aPL antibodies. The current recommendation for the treatment of obstetric 
APS is to initiate LDA plus LMWH at therapeutic doses.
All women should be evaluated for risk factors for venous thromboembo-
lism and should receive postpartum thromboprophylaxis. The Royal College of 
Gynecology in the United Kingdom, for example, recommends, for aPL-positive 
women without clinical manifestations of APS, 7 days after thromboprophylaxis 
of labor, and for women with APS, this extends to 6 weeks. All women with APS 
can deliver natural light, unless there are obstetric reasons to suggest otherwise. 
In addition, all women should be encouraged to stop smoking and reduce/discon-
tinue alcohol consumption in accordance with the national pregnancy guidelines. 
Patients with a recent thrombotic event in the last 3 months, particularly high blood 
pressure and/or uncontrolled, should be encouraged to postpone new pregnancies. 
Patients with pulmonary hypertension in general are advised not to get pregnant. 
Women with previous thrombosis should receive long-term anticoagulation once 
the risk of postpartum hemorrhage has stabilized. Both AVK (antivitamin K) and 
heparins are compatible with breastfeeding. With respect to fetal monitoring during 
pregnancy, the bilateral uterine notch between 23 and 25 weeks of gestation has 
been shown to be an independent risk factor for the development of early-onset 
preeclampsia and gestational hypertension. Therefore, the bilateral notch of the 
uterine artery should be considered in the risk assessment for the development of 
these pregnancy complications. The evaluation of thrombotic risk should also be 
considered in patients with a history of obstetric primary health center. Among 
others, Lefevre et al. demonstrated that patients with obstetric APS have a higher 
thrombotic risk compared to healthy women (3.3 versus 0–0.5/100 patient years), 
even if treated with LDA. Similarly, in a 10-year observational study of 1592 women 
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with pure obstetric SAP and no history of thrombosis, Gris et al. demonstrated 
that the LA was a risk factor for superficial and superficial venous thrombosis and 
unprovoked distal and similar results have been demonstrated in other studies.
The current treatment to prevent obstetric morbidity in primary health center 
(PHC) has improved the outcome of pregnancy at a rate of live births of more than 
70%. Given that 30% of women continue to have complications during pregnancy, 
international groups are currently evaluating different options to improve preg-
nancy outcomes in women with APS. The additional use of low doses of steroids has 
been evaluated in refractory APS. It has been suggested that intravenous immu-
noglobulin improves pregnancy complications in obstetric PHC. Treatment with 
pravastatin suggests a beneficial role in those women with preeclampsia related to 
established aPL. In their case series, 11 patients are treated with pravastatin 20 mg/day  
in addition to the standard treatment, while the controls continued alone with 
LDA and LMWH. In all patients exposed to pravastatin, signs of preeclampsia, 
such as blood pressure and proteinuria, improved and signs of placental perfusion 
remained stable without further deterioration compared to the control group. HCQ 
has also been evaluated. The HCQ immunomodulator can have beneficial effects 
not only in the treatment of thrombotic APS but also in the prevention of preg-
nancy complications [10]. The European randomized controlled multicenter trial 
“HYPATIA” will evaluate the role of HCQ versus placebo in pregnant women with 
aPL and, hopefully, provide stronger evidence on the use of HCQ in this context. 
Complement activation, and therefore a potential role for eculizumab, has also been 
introduced as a potential target for therapy with APS. The participation of comple-
ment activation was investigated for the first time in murine models of pregnancy 
morbidities related to aPL, and increasing evidence is emerging from both in vitro 
and in vivo studies. The complement can be activated by binding of the C3 frag-
ment to the Fc receptor of aPL antibodies or by the formation of autoantibodies 
against C1q, which are frequently detected in patients with APS. The activation of 
the complement pathway and, consequently, the production of inflammatory mol-
ecules such as C5a by aPL, can directly activate platelets and monocytes, inducing 
the coagulation cascade, which leads to the clinical manifestations of APS. Although 
in the current literature several case reports describe the successful use of eculi-
zumab in severe cases of APS, such as catastrophic antiphospholipid syndrome 
(CAPS) and cases of APS and thrombotic microangiopathy, the potential role of 
eculizumab should be further investigated.
12. Neonatal lupus
Pregnancies in women with anti-Ro and anti-La have an increased risk of devel-
oping neonatal lupus (NLS) with or without lupus. Maternal antibodies cross the 
placental barrier giving a passively acquired fetal autoimmunity. Cutaneous lesions 
of subacute lupus and hematologic and/or hepatic alterations of the NLS tend to 
resolve with the elimination of maternal antibodies from 6 to 8 months of age, but 
the lesion of the developing fetal cardiac conduction pathway can be irreversible. 
Cardiac injuries include conduction defects, structural abnormalities, cardiomyopa-
thy, and congestive heart failure, but the most serious complication is the develop-
ment of irreversible complete heart block (CHB), which is associated with a high 
fetal mortality of 20%. NLS can affect 2% of pregnancies exposed to anti-Ro, but 
recurrence rates in new pregnancies are 16–20% after a first NLS event. The majority 
(up to 70%) of the survivors require the insertion of a permanent pacemaker and 
periodic changes of the same as the child will grow. The CHB may be preceded by 
lower degrees of driving delays, although it may be sudden onset. Most of the events 
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occur between 18 and 24 weeks of gestation, but there are later cases, and even post-
partum CHB has been described. Early detection and initiation of treatment could 
stop progression to CHB, but reversal of established CHB has not been reported. 
Multiple monitoring tools have been proposed for the early detection of cardiac 
conduction disorder, but fetal Doppler echocardiography remains the most widely 
used method. The most vulnerable period is between 18 and 24 weeks of pregnancy, 
so it is recommended in this period of pregnancy to monitor weekly all exposed 
fetuses, and then every 2 weeks. The detection of an early conduction defect with a 
prolonged RP interval should indicate the start of a prophylactic treatment to avoid 
CHB, although we do not have any effective guidelines. The maternal administration 
of fluorinated corticosteroids and beta-agonists has shown benefits in some specific 
cases. The treatment of established CHB remains an unresolved problem with mini-
mal benefit with any available approach. The high risk of recurrence in subsequent 
pregnancies justifies prophylactic therapy for pregnancies at risk. The beneficial 
effects of IVIg were reported in open studies, but two randomized controlled trials 
were negative. Both trials have been criticized for their methodology, but the use of 
IVIg in this context can still be considered as an option. HCQ again deserves special 
mention. Several studies have shown that HCQ reduces the risk of cardiac NLS in 
fetuses at risk and possible recurrences. In view of the multiple beneficial effects of 
HCQ, it is indicated in all pregnant women with lupus and anti-Ro [11].
13. Delivery
Women with SLE have an increased risk of preterm birth. This can occur 
spontaneously or due to maternal and/or fetal complications, such as a flare of 
severe lupus, preeclampsia, and FGR. Between 24 and 34 weeks of gestation, the 
acceleration of fetal lung maturation is essential, with steroids (preferably beta-
methasone), regardless of any steroid administered previously. Magnesium sulfate 
when gestational age is <32 weeks, due to its neuroprotective benefits for the fetus, 
should be administered in cases of severe preeclampsia. The objective in a pregnant 
patient with SLE should be a spontaneous delivery at term via the vagina. However, 
available data have revealed that women with SLE undergo a higher cesarean section 
(>33%, odds ratio (OR) 1.7, confidence interval (CI) 95% 1.6–1.9). Despite this, it is 
recommended that cesarean sections be reserved only for obstetric indications, due 
to their additional risk factor for venous thromboembolism (VTE), blood loss and 
infection, and repercussions for future pregnancies. Intravenous hydrocortisone 
may be necessary to overcome the physiological stress of labor if long-term oral ste-
roids, which are very common in SLE, have been taken. The standard prophylactic 
LMWH should be discontinued at the start of spontaneous delivery and the night 
before induced labor or elective cesarean section. Regional anesthesia (epidural or 
spinal) can be performed 12 hours after the last dose of LMWH.
14. Postpartum care
In the puerperium, we must control the activity of the SLE for the detection of 
flare or coexisting preeclampsia. The treatment for postpartum active SLE is similar 
to that of nonpregnant women. However, the use of some drugs may have effects 
on the nursing infant. Therefore, the risks and benefits of continuing to breastfeed 
should be clarified to the nursing mother. All women who received antenatal 
LMWH should continue using it for 6 weeks after delivery, in a prophylactic dose, 
since the puerperium is also a period of increased risk of VTE. In patients with 
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SLE, postpartum advice to offer safe contraception is particularly important. Good 
options are long-acting reversible contraception methods. The use of progestogens 
is only safe and can become an appropriate option. Contraceptives containing 
estrogen will not use women with aPL or APS, SLE with moderate to severe flare, 
lupus nephritis, and some other conditions, such as hypertension, smoking, obesity, 
or previous VTE, since they increase the risk of VTE. In cases of well-defined SLE 
with stable and/or mild disease, the use of combined oral contraceptives may be 
indicated. Contraceptive barrier methods have a high failure rate (15–32%) and, 
therefore, should not be used as a single method.
Abbreviations
SLE systemic lupus erythematosus
LA lupus anticoagulant
aCL anticardiolipin antibody
aβ2GPI anti-β2 glycoprotein I
aPL antiphospholipid antibody
HELLP hemolysis, elevated liver enzymes, and low platelets
sFlt-1 soluble fms-like tyrosine kinase
PlGF placental growth factor
CYC cyclophosphamide
LMWH low molecular weight heparin
ESR erythrocyte sedimentation ratio
MMF mycophenolate mofetil
HPA hypothalamic pituitary axis
AMH anti-mulleriana hormone
GnRH gonadotrophic hormone receptor
IUDs intrauterine devices
IVF in vitro fertilization
OHSS ovarian hyperstimulation syndrome
SLEPDAI SLE pregnancy disease activity index
LAI-P lupus activity index pregnancy
FGR fetal growth restriction
NSAIDs nonsteroidal anti-inflammatory drugs
ACE angiotensin-converting enzyme
DMPA depot medroxyprogesterone acetate
SLEDAI SLE disease activity index
PHC primary health center
FDA Federal Drug Association
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